|Articles|November 24, 2003

Third oral agent for ED wins FDA approval

The FDA has approved tadalafil (Cialis), a new oral PDE-5 inhibitor, for the treatment of erectile dysfunction.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe

Related Content

Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer

ByLaura Bukavina, MD, MPH, MSc,Gabriela M. Diáz, MD

August 3rd 2026

Blur image of medical clinic | Image Credit: © zephyr_p - stock.adobe.com

Individualizing androgen pathway therapy in mCSPC

ByUrology Times staff

August 1st 2026

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

ByHannah Clarke

July 31st 2026

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

ByJoshua Lang, MD, MS

July 31st 2026

Testosterone deficiency: FAQs from the AUA guideline

ByHannah Clarke

July 30th 2026

Latest CME

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Video

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Third oral agent for ED wins FDA approval

Related Content

Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer

Individualizing androgen pathway therapy in mCSPC

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice

Testosterone deficiency: FAQs from the AUA guideline

Latest CME

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Trending on Urology Times

FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC

Laura Bukavina, MD, and Gabriela Díaz, MD, on the rise of young-onset bladder cancer

Individualizing androgen pathway therapy in mCSPC

BOND-003 Cohort C: Efficacy Results

BOND-003 Cohort C: Study Design and Patient Population